The DOI matches its Crossref record; 194 of the 194 references it cites were found in a registry or an index.
The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases
Open accessAbstract
An intense, stereotyped inflammatory response occurs in response to ischaemic and non-ischaemic injury to the myocardium. The NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome is a finely regulated macromolecular protein complex that senses the injury and triggers and amplifies the inflammatory response by activation of caspase 1; cleavage of pro-inflammatory cytokines, such as pro-IL-1β and pro-IL-18, to their mature forms; and induction of inflammatory cell death (pyroptosis). Inhibitors of the NLRP3 inflammasome and blockers of IL-1β and IL-18 activity have been shown to reduce injury to the myocardium and pericardium, favour resolution of the inflammation and preserve cardiac function. In this Review, we discuss the components of the NLRP3 inflammasome and how it is formed and activated in various ischaemic and non-ischaemic cardiac pathologies (acute myocardial infarction, cardiac dysfunction and remodelling, atherothrombosis, myocarditis and pericarditis, cardiotoxicity and cardiac sarcoidosis). We also summarize current preclinical and clinical evidence from studies of agents that target the NLRP3 inflammasome and related cytokines. The NLRP3 inflammasome can sense cardiac ischaemic and non-ischaemic injury, amplify the inflammatory response and induce inflammatory cell death. In this Review, Toldo and Abbate describe the role of the NLRP3 inflammasome in numerous cardiac pathologies and summarize evidence on the use of agents targeting the NLRP3 inflammasome and related cytokines. The NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome is a macromolecular, intracellular structure that functions as a sensor for injury. NLRP3 inflammasome activation amplifies the inflammatory response and tissue injury by regulating the processing and release of IL-1β and IL-18 and causing cell death by pyroptosis. Preclinical studies with genetically modified mouse models and the use of targeted inhibitors have shown that inhibiting activation of the NLRP3 inflammasome reduces inflammatory injury and adverse remodelling. Colchicine, a non-selective NLRP3 inflammasome inhibitor, has been shown to be efficacious in the treatment of pericarditis and in reducing atherothrombotic risk in patients with coronary artery disease. IL-1 blockers have been shown in phase Ib–III trials to reduce cardiovascular risk and morbidity across a wide range of cardiovascular diseases, including myocardial infarction, heart failure, acute myocarditis and recurrent pericarditis. Targeted NLRP3 inflammasome inhibitors and blockers of IL-18 and IL-6, downstream of IL-1, are in clinical testing for various cardiovascular diseases. The NACHT, LRR and PYD domains-containing protein 3 (NLRP3) inflammasome is a macromolecular, intracellular structure that functions as a sensor for injury. NLRP3 inflammasome activation amplifies the inflammatory response and tissue injury by regulating the processing and release of IL-1β and IL-18 and causing cell death by pyroptosis. Preclinical studies with genetically modified mouse models and the use of targeted inhibitors have shown that inhibiting activation of the NLRP3 inflammasome reduces inflammatory injury and adverse remodelling. Colchicine, a non-selective NLRP3 inflammasome inhibitor, has been shown to be efficacious in the treatment of pericarditis and in reducing atherothrombotic risk in patients with coronary artery disease. IL-1 blockers have been shown in phase Ib–III trials to reduce cardiovascular risk and morbidity across a wide range of cardiovascular diseases, including myocardial infarction, heart failure, acute myocarditis and recurrent pericarditis. Targeted NLRP3 inflammasome inhibitors and blockers of IL-18 and IL-6, downstream of IL-1, are in clinical testing for various cardiovascular diseases.
Overview
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
1 retracted
O’Riordan, C. E., Purvis, G. S. D., Collotta, D., Chiazza, F., Wissuwa, B., Zoubi, S. A., Stiehler, L., Märtin, L., Coldewey, S. M., Collino, M., et al. (2019) · Frontiers in Immunology · doi:10.3389/fimmu.2019.02129 · Cited by 35
RetractedAntiinflammatory Therapy with Canakinumab for Atherosclerotic Disease
Ridker, P. M., Everett, B. M., Thuren, T., MacFadyen, J. G., Chang, W. H., Ballantyne, C., Fonseca, F., Nicolau, J., Koenig, W., Anker, S. D., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1707914 · Cited by 9,482
Heart Disease and Stroke Statistics—2022 Update: A Report From the American Heart Association
Tsao, C. W., Aday, A. W., Almarzooq, Z. I., Alonso, A., Beaton, A. Z., Bittencourt, M. S., Boehme, A. K., Buxton, A. E., Carson, A. P., Commodore-Mensah, Y., et al. (2022) · Circulation · doi:10.1161/cir.0000000000001052 · Cited by 5,987
A role for mitochondria in nlrp3 inflammasome activation
Zhou, R., Yazdi, A. S., Menu, P., & Tschopp, J. (2011) · Nature · doi:10.1038/nature09663 · Cited by 5,602
The NLRP3 inflammasome: molecular activation and regulation to therapeutics
Swanson, K. V., Deng, M., & Ting, J. P.-Y. (2019) · Nature Reviews Immunology · doi:10.1038/s41577-019-0165-0 · Cited by 4,884
Autophagy and Viruses: Adversaries or Allies?
Dong, X., & Levine, B. (2013) · Journal of Innate Immunity · doi:10.1159/000346388 · Cited by 4,430
NLRP3 inflammasomes are required for atherogenesis and activated by cholesterol crystals
Duewell, P., Kono, H., Rayner, K. J., Sirois, C. M., Vladimer, G., Bauernfeind, F. G., Abela, G. S., Franchi, L., Nuñez, G., Schnurr, M., et al. (2010) · Nature · doi:10.1038/nature08938 · Cited by 4,026 · cited 2×
“Deletion of the Nlrp3 , Asc and Il-1α/β genes in the bone marrow of mice with hypercholesterolaemia prevented the development and modified the characteristics of atherosclerotic plaques 100–103 .”
Inflammasome-activated gasdermin D causes pyroptosis by forming membrane pores
Liu, X., Zhang, Z., Ruan, J., Pan, Y., Magupalli, V. G., Wu, H., & Lieberman, J. (2016) · Nature · doi:10.1038/nature18629 · Cited by 3,202
Efficacy and safety of low-dose colchicine after myocardial infarction
Tardif, J.-C., Kouz, S., Waters, D. D., Bertrand, O. F., Diaz, R., Maggioni, A. P., Pinto, F. J., Ibrahim, R., Gamra, H., Kiwan, G. S., et al. (2019) · New England Journal of Medicine · doi:10.1056/nejmoa1912388 · Cited by 3,159
Nakahira, K., Haspel, J. A., Rathinam, V. A. K., Lee, S.-J., Dolinay, T., Lam, H. C., Englert, J. A., Rabinovitch, M., Cernadas, M., Kim, H. P., et al. (2011) · Nature Immunology · doi:10.1038/ni.1980 · Cited by 3,049
Cited by
Tan, X., Wang, X., Xu, S., Zeng, Y., Zhang, G., Xu, A., Jiang, Y., Jiang, H., Song, Y., Fan, J., et al. (2025) · Journal of Inflammation Research · doi:10.2147/jir.s495784 · Cited by 8
Metadata
- Authors
- Toldo, S., & Abbate, A.
- Venue
- Nature Reviews Cardiology
- Published
- 2023-11-03
- Volume
- 21
- Issue
- 4
- Pages
- 219-237
- ISSN
- 1759-5002 (ISSN-L)
- 1759-5010
- OpenAlex
- W4388283199
- Cited by
- 411
- References
- 194
- FWCI
- 10.27
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. https://app.cochat.ai/papers/10.1038/s41569-023-00946-3
- The paper
- Toldo, S., & Abbate, A. (2024). The role of the NLRP3 inflammasome and pyroptosis in cardiovascular diseases. Nature Reviews Cardiology. https://doi.org/10.1038/s41569-023-00946-3
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.